Treatment of Neurological Symptoms in Wilson Disease

  • Ana Vives-RodriguezEmail author
  • Daphne Robakis
  • Nigel S. Bamford
Part of the Clinical Gastroenterology book series (CG)


Brain copper accumulation commonly causes neurological symptoms in Wilson disease (WD). Many of the neurological manifestations that are present in WD involve movement disorders such as tremor, dysarthria, parkinsonism, dystonia, and gait impairment. Current de-coppering therapy provides in most cases only partial improvement of the neurological aspects of WD, and the use of medications to treat residual neurological symptoms is commonly required to improve patients’ quality of life. The evidence assessing the efficacy of different therapeutic options for movement disorders in WD is limited. This chapter aims to review the most common neurological manifestations in WD and the therapeutic options currently available.


Wilson disease Neurological manifestations Copper Tremor Dystonia Parkinsonism 


  1. 1.
    Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore). 1992;71(3):139–64.CrossRefGoogle Scholar
  2. 2.
    Starosta-Rubinstein S, Young AB, Kluin K, Hill G, Aisen AM, Gabrielsen T, et al. Clinical assessment of 31 patients with Wilson disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol. 1987;44(4):365–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Dastur DK, Manghani DK, Wadia NH. Wilson disease in India. I. Geographic, genetic, and clinical aspects in 16 families. Neurology. 1968;18(1 Pt 1):21–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore). 2007;86(2):112–21.CrossRefGoogle Scholar
  5. 5.
    Huang CC, Chu NS. Wilson disease: clinical analysis of 71 cases and comparison with previous Chinese series. J Formos Med Assoc Taiwan Yi Zhi. 1992;91(5):502–7.PubMedGoogle Scholar
  6. 6.
    Lorincz MT. Neurologic Wilson disease. Ann N Y Acad Sci. 2010;1184:173–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson disease: a cohort study. Gut. 2007;56(1):115–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson disease: a prospective study of 45 cases. J Neurol. 1991;238(5):281–7.PubMedGoogle Scholar
  9. 9.
    Członkowska A, Litwin T, Chabik G. Wilson disease: neurologic features. Handb Clin Neurol. 2017;142:101–19.CrossRefPubMedGoogle Scholar
  10. 10.
    Nazer H, Brismar J, al-Kawi MZ, Gunasekaran TS, Jorulf KH. Magnetic resonance imaging of the brain in Wilson disease. Neuroradiology. 1993;35(2):130–3.CrossRefPubMedGoogle Scholar
  11. 11.
    Algin O, Taskapilioglu O, Hakyemez B, Ocakoglu G, Yurtogullari S, Erer S, et al. Structural and neurochemical evaluation of the brain and pons in patients with Wilson disease. Jpn J Radiol. 2010;28(9):663–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry. 2014;36(1):53–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Machado A, Chien HF, Deguti MM, Cançado E, Azevedo RS, Scaff M, et al. Neurological manifestations in Wilson disease: report of 119 cases. Mov Disord Off J Mov Disord Soc. 2006;21(12):2192–6.CrossRefGoogle Scholar
  14. 14.
    Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med. 1991;115(9):720–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Brewer GJ, Fink JK, Hedera P. Diagnosis and treatment of Wilson disease. Semin Neurol. 1999;19(3):261–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Hölscher S, Leinweber B, Hefter H, Reuner U, Günther P, Weiss KH, et al. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64(2):83–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Litwin T, Dušek P, Członkowska A. Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol. 2017;142:211–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Louis ED. Diagnosis and management of tremor. Contin Minneap Minn. 2016;22(4 Movement Disorders):1143–58.Google Scholar
  19. 19.
    Ondo W. Essential tremor: what we can learn from current pharmacotherapy. Tremor Hyperkinetic Mov N Y N. 2016;6:356.Google Scholar
  20. 20.
    Svetel M, Kozić D, Stefanova E, Semnic R, Dragasevic N, Kostic VS. Dystonia in Wilson disease. Mov Disord Off J Mov Disord Soc. 2001;16(4):719–23.CrossRefGoogle Scholar
  21. 21.
    Marsden CD, editor. Movement disorders: neurology 2: Buttwerworth-Heinemann Oxford, UK; 2013. 394 p.Google Scholar
  22. 22.
    Deuschl G. Dystonic tremor. Rev Neurol (Paris). 2003;159(10 Pt 1):900–5.Google Scholar
  23. 23.
    Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry. 2014;85(7):759–69.CrossRefPubMedGoogle Scholar
  24. 24.
    Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders, vol. 3330: Elsevier Health Sciences Saunders Elsevier Philadelphia, USA; 2011.Google Scholar
  25. 25.
    Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999;354(1381):259–68.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Dressler D, Altenmueller E, Bhidayasiri R, Bohlega S, Chana P, Chung TM, et al. Strategies for treatment of dystonia. J Neural Transm Vienna Austria 1996. 2016;123(3):251–8.Google Scholar
  27. 27.
    Thenganatt MA, Jankovic J. Treatment of dystonia. Neurother J Am Soc Exp Neurother. 2014;11(1):139–52.CrossRefGoogle Scholar
  28. 28.
    Maltese M, Martella G, Madeo G, Fagiolo I, Tassone A, Ponterio G, et al. Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors. Mov Disord Off J Mov Disord Soc. 2014;29(13):1655–65.CrossRefGoogle Scholar
  29. 29.
    Fahn S. High dosage anticholinergic therapy in dystonia. Neurology. 1983;33(10):1255–61.CrossRefPubMedGoogle Scholar
  30. 30.
    McFarland NR. Diagnostic approach to atypical Parkinsonian syndromes. Contin Minneap Minn. 2016;22(4 Movement Disorders):1117–42.Google Scholar
  31. 31.
    da Silva-Júnior FP, Carrasco AE a B, da Silva Mendes AM, Lopes AJT, Nobre E Souza MA, de Bruin VMS. Swallowing dysfunction in Wilson disease: a scintigraphic study. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2008;20(4):285–90.CrossRefGoogle Scholar
  32. 32.
    Członkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M. Wilson disease-cause of mortality in 164 patients during 1992–2003 observation period. J Neurol. 2005;252(6):698–703.CrossRefPubMedGoogle Scholar
  33. 33.
    Wilson DC, Phillips MJ, Cox DW, Roberts EA. Severe hepatic Wilson disease in preschool-aged children. J Pediatr. 2000;137(5):719–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Iorio R, D’Ambrosi M, Mazzarella G, Varrella F, Vecchione R, Vegnente A. Early occurrence of hypertransaminasemia in a 13-month-old child with Wilson disease. J Pediatr Gastroenterol Nutr. 2003;36(5):637–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Tissières P, Chevret L, Debray D, Devictor D. Fulminant Wilson disease in children: appraisal of a critical diagnosis. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2003;4(3):338–43.Google Scholar
  36. 36.
    Roberts EA, Socha P. Wilson disease in children. Handb Clin Neurol. 2017;142:141–56.CrossRefPubMedGoogle Scholar
  37. 37.
    Noureen N, Rana MT. Neurological Wilson disease in children: a three years experience from Multan. JPMA J Pak Med Assoc. 2011;61(8):743–8.PubMedGoogle Scholar
  38. 38.
    Członkowska A, Tarnacka B, Möller JC, Leinweber B, Bandmann O, Woimant F, et al. Unified Wilson disease rating scale – a proposal for the neurological scoring of Wilson disease patients. Neurol Neurochir Pol. 2007;41(1):1–12.PubMedGoogle Scholar
  39. 39.
    Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJG, et al. Evaluation of the Unified Wilson Disease Rating Scale (UWDRS) in German patients with treated Wilson disease. Mov Disord Off J Mov Disord Soc. 2008;23(1):54–62.CrossRefGoogle Scholar
  40. 40.
    Volpert HM, Pfeiffenberger J, Gröner JB, Stremmel W, Gotthardt DN, Schäfer M, et al. Comparative assessment of clinical rating scales in Wilson disease. BMC Neurol. 2017;17(1):140.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatol Baltim Md. 2008;47(6):2089–111.CrossRefGoogle Scholar
  42. 42.
    European Association for Study of Liver. EASL clinical practice guidelines: Wilson disease. J Hepatol. 2012;56(3):671–85.CrossRefGoogle Scholar
  43. 43.
    Ranjan A, Kalita J, Kumar S, Bhoi SK, Misra UK. A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg. 2015;138:31–6.CrossRefPubMedGoogle Scholar
  44. 44.
    King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, et al. Cranial MR imaging in Wilson disease. AJR Am J Roentgenol. 1996;167(6):1579–84.CrossRefPubMedGoogle Scholar
  45. 45.
    Litwin T, Dzieżyc K, Poniatowska R, Członkowska A. Effect of liver transplantation on brain magnetic resonance imaging pathology in Wilson disease: a case report. Neurol Neurochir Pol. 2013;47(4):393–7.PubMedGoogle Scholar
  46. 46.
    Kim TJ, Kim IO, Kim WS, Cheon JE, Moon SG, Kwon JW, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. Am J Neuroradiol. 2006;27(6):1373–8.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ana Vives-Rodriguez
    • 1
    Email author
  • Daphne Robakis
    • 1
  • Nigel S. Bamford
    • 1
    • 2
    • 3
  1. 1.Department of NeurologyYale UniversityNew HavenUSA
  2. 2.Department of PediatricsYale UniversityNew HavenUSA
  3. 3.Department of Cellular and Molecular PhysiologyYale UniversityNew HavenUSA

Personalised recommendations